PARIS — The Food and Drug Administration has approved a voice-guided injection device made by Sanofi for severe allergic reactions, the drug maker said Monday.
The French drug maker announced the approval of Auvi-Q (epinephrine), calling it the first epinephrine auto-injector with audio and visual cues that guides users through the injection process. Sanofi US licensed the North American commercialization rights to Auvi-Q from Intelliject, which has retained commercialization rights for the rest of the world.
"As a company committed to patient-centered care, our focus is on creating innovative solutions that make a difference in the lives of people," Sanofi president for North American Pharmaceuticals Anne Whitaker said. "Auvi-Q delivers on this by offering a state-of-the-art epinephrine auto-injector device that addresses the needs of patients at risk for life-threatening allergic reactions and their caregivers."